JP2022547604A5 - - Google Patents

Info

Publication number
JP2022547604A5
JP2022547604A5 JP2022516271A JP2022516271A JP2022547604A5 JP 2022547604 A5 JP2022547604 A5 JP 2022547604A5 JP 2022516271 A JP2022516271 A JP 2022516271A JP 2022516271 A JP2022516271 A JP 2022516271A JP 2022547604 A5 JP2022547604 A5 JP 2022547604A5
Authority
JP
Japan
Application number
JP2022516271A
Other languages
Japanese (ja)
Other versions
JPWO2021048821A5 (https=
JP2022547604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058482 external-priority patent/WO2021048821A1/en
Publication of JP2022547604A publication Critical patent/JP2022547604A/ja
Publication of JP2022547604A5 publication Critical patent/JP2022547604A5/ja
Publication of JPWO2021048821A5 publication Critical patent/JPWO2021048821A5/ja
Pending legal-status Critical Current

Links

JP2022516271A 2019-09-13 2020-09-12 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用 Pending JP2022547604A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900310P 2019-09-13 2019-09-13
US62/900,310 2019-09-13
US202063031687P 2020-05-29 2020-05-29
US63/031,687 2020-05-29
PCT/IB2020/058482 WO2021048821A1 (en) 2019-09-13 2020-09-12 Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness

Publications (3)

Publication Number Publication Date
JP2022547604A JP2022547604A (ja) 2022-11-14
JP2022547604A5 true JP2022547604A5 (https=) 2023-09-20
JPWO2021048821A5 JPWO2021048821A5 (https=) 2023-09-20

Family

ID=72521681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516271A Pending JP2022547604A (ja) 2019-09-13 2020-09-12 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用

Country Status (11)

Country Link
US (1) US20220331303A1 (https=)
EP (1) EP4028003A1 (https=)
JP (1) JP2022547604A (https=)
KR (1) KR20220062361A (https=)
CN (1) CN114555083A (https=)
AU (1) AU2020347578A1 (https=)
BR (1) BR112022004576A2 (https=)
CA (1) CA3154320A1 (https=)
CO (1) CO2022004589A2 (https=)
MX (1) MX2022003017A (https=)
WO (1) WO2021048821A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2021205892B2 (en) 2020-01-10 2026-04-23 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024075825A1 (ja) 2022-10-07 2024-04-11 キッセイ薬品工業株式会社 シクロペンタン化合物
EP4719397A1 (en) * 2023-06-02 2026-04-08 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
LT3984994T (lt) * 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022547604A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)